#patent-disputes tag

BioNTech to Buy CureVac in $1.25B Stock Deal That Would Also End mRNA Patent Dispute - MedCity News

BioNTech's acquisition of CureVac represents a strategic move to mitigate legal risks while combining their mRNA capabilities to enhance cancer treatment development.

NYC startup

Intellectual property law

fromIPWatchdog.com | Patents & Intellectual Property Law

2 weeks ago

Other Barks & Bites for Friday, May 30: Eighth Circuit Avoids Knowledge Standard Question Left by Unicolors; SCOTUS Denies Petition on Enablement Standard for Prior Art; USIJ Urges FTC to Look at PTAB Abuse

Temporary restraining order against Shira Perlmutter's firing denied, but legal avenues may persist.

Eighth Circuit avoids key copyright ruling, leaving important questions unresolved.

General Motors invests $888 million in next-gen V-8 engine plant.

Intel has another shot at reversing $3 billion in damages over patent disputes.

Intellectual property law

fromIPWatchdog.com | Patents & Intellectual Property Law

1 month ago

Pharma Playbook: What Practitioners Can Learn from Early UPC Litigation

The Unified Patent Court (UPC) is now central to pharmaceutical patent disputes in Europe, affecting strategies for innovators and generics.

EPO oppositions significantly impact UPC proceedings, influencing both patent validity and injunctive relief.

#patent-disputes#patent-disputes

BioNTech to Buy CureVac in $1.25B Stock Deal That Would Also End mRNA Patent Dispute - MedCity News

Other Barks & Bites for Friday, May 30: Eighth Circuit Avoids Knowledge Standard Question Left by Unicolors; SCOTUS Denies Petition on Enablement Standard for Prior Art; USIJ Urges FTC to Look at PTAB Abuse

Pharma Playbook: What Practitioners Can Learn from Early UPC Litigation

#patent-disputes
#patent-disputes